Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460096 · ClinicalTrials.gov registry record · Phase 2
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
A Phase 2 study, sponsored by Kamada.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00460096 is a Phase 2 study that has completed, run by Kamada. The registered enrollment target is 50 participants.
The verdict
NCT00460096, a Phase 2 study, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary purpose of this Phase II/III study is to demonstrate that Kamada-API, a new API concentrate manufactured by Kamada Ltd., is comparable to a currently marketed API product.
Interventions
- DRUG Kamada-API
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460096
The ClinicalTrials.gov registry entry for NCT00460096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kamada, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kamada-API is the first listed.
NCT00460096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460096 about?
NCT00460096 is a clinical study titled "Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency". The primary purpose of this Phase II/III study is to demonstrate that Kamada-API, a new API concentrate manufactured by Kamada Ltd., is comparable to a currently marketed API product.
What is the current status of trial NCT00460096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2007-03. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00460096?
The interventions under investigation include: Kamada-API (DRUG).
Who is sponsoring clinical trial NCT00460096?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.